TO Ka Fai
Name : TO Ka Fai 杜家輝
Title :

Chairman, Department of Anatomical and Cellular Pathology

Director, Pathology Teaching Laboratory

Associate Director, State Key Laboratory in Oncology in South China (CUHK)

Professor, Institute of Digestive Disease
Home Department :  Anatomical and Cellular Pathology
Email :
Website :


Professor To is the Chairman of the Department of Anatomical & Cellular Pathology, The Chinese University of Hong Kong (CUHK) and Honorary Chief of Service in the Department of Anatomical & Cellular Pathology, Prince of Wales Hospital, Hong Kong. He is the Associate Director of State Key Laboratory in Oncology in South China (CUHK) and core member of the Institute of Digestive Disease, CUHK.

Professor To's research interests include common Asian Cancer, gastrointestinal (GI) pathology and molecular diagnostic. He has published over 300 articles in the international peer review journals, including Cancer Cell, Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine, Cancer Research, The New England Journal of Medicine, The Lancet, Gastroenterology, and Hepatology. He actively participates in clinical trials and served as consultant for clinical or drug trials including Pathology Committee in the International Association for the Study of Lung Cancer (IASLC)

Specialised Research Area(s):

  • Common Asian Cancer, in particular nasopharyngeal carcinoma and the potential application of molecular bio-markers.
  • Pathology related to Helicobacter- pylori associated gastritis.
  • Renal pathology, in particular IgA glomerulonephritis.
  • Paediatric pathology with current studies related to sudden infant death syndrome.
  • Infectious pathology.

Selected Publications:

1. Cheng, A. S., Li, M. S., Kang, W., Cheng, V. Y., Chou, J. L., Lau, S. S., Go, M. Y., Lee, C. C., Ling, T. K., Ng, E. K., Yu, J., Huang, T. H., To, K. F., Chan, M. W., Sung, J. J., & Chan, F. K. (2012). Helicobacter pylori Causes Epigenetic Dysregulation of FOXD3 to Promote Gastric Carcinogenesis. Gastroenterology, [Epub ahead of print]

2. Yeo, W., Chung, H. C., Chan, S. L., Wang, L. Z., Lim, R., Picus, J., Boyer, M., Mo, F. K., Koh, J., Rha, S. Y., Hui, E. P., Jeung, H. C., Roh, J. K., Yu, S. C., To, K. F., Tao, Q., Ma, B. B., Chan, A. W., Tong, J. H., Erlichman, C., Chan, A. T., & Goh, B. C. (2012). Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 30(27), 3361-3367.

3. Lung, R. W., Wang, X., Tong, J. H., Chau, S. L., Lau, K. M., Cheng, S. H., Woo, J. K., Woo, J., Leung, P. C., Ng, M. H., Tang, N. L., & To, K. F. (2012). A single nucleotide polymorphism in microRNA-146a is associated with the risk for nasopharyngeal carcinoma. Molecular Carcinogenesis, [Epub ahead of print]

4. Kang, W., Tong, J. H., Chan, A. W., Lung, R. W., Chau, S. L., Wong, Q. W., Wong, N., Yu, J., Cheng, A. S., & To, K. F. (2012). Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One, 7(3), e33919.

5. Lo, K. W., Chung, G. T., & To, K. F. (2012). Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Seminar in Cancer Biology, 22(2), 79-86.

6. Wang, H. Y., Sun, B. Y., Zhu, Z. H., Chang, E. T., To, K. F., Hwang, J. S., Jiang, H., Kam, M. K., Chen, G., Cheah, S. L., Lee, M., Liu, Z. W., Chen, J., Zhang, J. X., Zhang, H. Z., He, J. H., Chen, F. L., Zhu, X. D., Huang, M. Y., Liao, D. Z., Fu, J., Shao, Q., Cai, M. B., Du, Z. M., Yan, L. X., Hu, C. F., Ng, H. K., Wee, J. T., Qian, C. N., Liu, Q., Ernberg, I., Ye, W., Adami, H. O., Chan, A. T., Zeng, Y. X., & Shao, J. Y. (2011). Eight-signature classifier for prediction of nasopharnyngeal carcinoma survival. Journal of Clinical Oncology, 29(34), 4516-4525.

7. Fukuoka, M., Wu, Y. L., Thongprasert, S., Sunpaweravong, P., Leong, S. S., Sriuranpong, V., Chao, T. Y., Nakagawa, K., Chu, D. T., Saijo, N., Duffield, E. L., Rukazenkov, Y., Speake, G., Jiang, H., Armour, A. A., To, K. F., Yang, J. C., & Mok, T. S. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology, 29(21), 2866-2874.

8. Kang, W., Tong, J. H., Chan, A. W., Lee, T. L., Lung, R. W., Leung, P. P., So, K. K., Wu, K., Fan, D., Yu, J., Sung, J. J., & To, K. F. (2011). Yes-associated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clinical Cancer Research, 17(8), 2130-2139.